Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeo Pharma Inc.

http://www.valeopharma.com

Latest From Valeo Pharma Inc.

Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars

Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.

Biosimilars Market Access

Who’s Hired? ANI Pharma Strengthens Leadership With Three New Executives

ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.

Leadership Strategy

Quebec To List Enoxaparin Biosimilar As Valeo Pharma Prepares Launch

Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.

Biosimilars Reimbursement

Valeo Pharma To Launch Enoxaparin In Canada Early Next Year

Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.

Biosimilars Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Valeo Pharmaceuticals
UsernamePublicRestriction

Register